ATRA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 38.73% compared to Atara Biotherapeutics's net margin of -49.65%. Atara Biotherapeutics's return on equity of -2818.48% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Atara Biotherapeutics has a consensus price target of $16.00, signalling upside risk potential of 81.41%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.67%. Given that Atara Biotherapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Atara Biotherapeutics is more attractive than NovaBay Pharmaceuticals.

Atara Biotherapeutics has a beta of 0.187, which suggesting that the stock is 81.26% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $98.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Atara Biotherapeutics's net income of $38M is higher than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.39x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nanoviricides has a net margin of 38.73% compared to Atara Biotherapeutics's net margin of --. Atara Biotherapeutics's return on equity of -2818.48% beat Nanoviricides's return on equity of --.

Atara Biotherapeutics has a consensus price target of $16.00, signalling upside risk potential of 81.41%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 330.46%. Given that Nanoviricides has higher upside potential than Atara Biotherapeutics, analysts believe Nanoviricides is more attractive than Atara Biotherapeutics.

Atara Biotherapeutics has a beta of 0.187, which suggesting that the stock is 81.26% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $98.1M, which are larger than Nanoviricides quarterly revenues of --. Atara Biotherapeutics's net income of $38M is higher than Nanoviricides's net income of -$2.2M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.39x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of 38.73% compared to Atara Biotherapeutics's net margin of --. Atara Biotherapeutics's return on equity of -2818.48% beat Oragenics's return on equity of --.

Atara Biotherapeutics has a consensus price target of $16.00, signalling upside risk potential of 81.41%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 588.14%. Given that Oragenics has higher upside potential than Atara Biotherapeutics, analysts believe Oragenics is more attractive than Atara Biotherapeutics.

Atara Biotherapeutics has a beta of 0.187, which suggesting that the stock is 81.26% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $98.1M, which are larger than Oragenics quarterly revenues of --. Atara Biotherapeutics's net income of $38M is higher than Oragenics's net income of -$2.2M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.39x versus 1.40x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 38.73% compared to Atara Biotherapeutics's net margin of --. Atara Biotherapeutics's return on equity of -2818.48% beat Theriva Biologics's return on equity of --.

Atara Biotherapeutics has a consensus price target of $16.00, signalling upside risk potential of 81.41%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1359.25%. Given that Theriva Biologics has higher upside potential than Atara Biotherapeutics, analysts believe Theriva Biologics is more attractive than Atara Biotherapeutics.

Atara Biotherapeutics has a beta of 0.187, which suggesting that the stock is 81.26% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $98.1M, which are larger than Theriva Biologics quarterly revenues of --. Atara Biotherapeutics's net income of $38M is higher than Theriva Biologics's net income of -$4.3M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.39x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.